;
November 11, 2019

Navigating the Challenges of Developing First of Kind Medical Devices

Eric Johnson and Andy Denison discuss the challenges unique to developing First of Kind medical devices (3 minutes).  
November 8, 2019
Innovation at REV.1 Engineering

Exit Horizon ~ M&A Activity and Private Equity Going into 2020

I recently had the opportunity to read Bain & Company’s annual Global Healthcare Private Equity and Corporate M&A Report – 2019.  While the current report looks back to 2018, it provides some insights as to what’s currently unfolding and what we might expect in 2020.  For mid-market medical device companies, these insights may open the door for strategic plays in the coming year. Let’s set the stage;  According to Bain’s earlier reporting, in 2017, Private […]
September 18, 2019
Innovation at REV.1 Engineering

REV•1 Engineering® Takes Early Phase Medical Device Development To The Next Level

It’s been a while since my last blog, as it’s been a busy summer here at REV•1 Engineering®.  Things have been so busy, our team has grown by 30% since the beginning of the year.  Not only have we been expanding our team of exceptional knowledge workers, we’ve added another compelling resource to the company; a Hewlett Packard Multi Jet Fusion 580 additive manufacturing system. If you’re unfamiliar with this technology (https://www8.hp.com/us/en/printers/3d-printers.html), it’s a real […]
July 29, 2019

REV•1 Engineering® Named As Exclusive Development Partner For Valvublator

Leonhardt Ventures taps REV•1 Engineering to design and develop Valvublator’s heart valve regeneration technology platform. MURRIETA, Calif. – July 26, 2019 – REV•1 Engineering has been selected as the exclusive design and development partner for the commercialization of Valvublator’s advanced, combination drug/device/biologics technology for regenerating human heart valves.  Valvublator’s platform integrates mechanical, electrical, therapeutical, and biological elements in a single, minimally invasive catheter to decalcify, cell sod and regenerate a patient’s heart valve leaflets.  It is intended […]
X
Schedule a Conversation
Contact Us